Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04866017 : Phase 3, Randomized, Open Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus cCRT Followed by Tislelizumab Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

ThreePhase Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Radiotherapy,Systemic therapy | LungNon-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase III study is comparing the effectiveness of different immunotherapies (ociperlimab, tislelizumab and durvalumab), combined with concurrent chemoradiation therapy, in people with previously untreated, locally advanced non-small cell lung cancer .
 

This trial is treating patients with non-small cell lung cancer.

This is a systemic therapy and radiation therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase 3, Randomized, Open Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus cCRT Followed by Tislelizumab Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Commercial Sponsor

BeiGene Australia Pty Ltd

Summary

Eligible participants will be randomly assigned to one of three arms. In Arm A (Experimental), participants will receive two cycles of ociperlimab (900mg intravenously [IV]) combined with tislelizumab (200mg IV) every 3 weeks (Q3W) with Concurrent Chemoradiotherapy (cCRT), followed by further treatment with ociperlimab (900mg IV) combined with tislelizumab (200mg IV) Q3W up to 1 year after the cCRT phase. In Arm B (Active Comparator), participants will receive tislelizumab (200mg IV Q3W) combined with cCRT, followed by further treatment with tislelizumab (200mg IV Q3W) up to 1 year after the cCRT phase. In Arm C, (Experimental), participants will receive two cycles of cCRT followed by treatment with durvalumab (10mg/kg IV) once every 2 weeks (Q2W) up to 1 year after the cCRT phase.

Recruiting Hospitals Read MoreRead more

Cabrini Education and Research Precinct
Malvern
Micheleine Uhe
muhe@cabrini.com.au
(03) 9508 3481

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next